Previous Close | 0.7049 |
Open | 0.6898 |
Bid | 0.6610 x 2200 |
Ask | 0.6659 x 1400 |
Day's Range | 0.6536 - 0.6900 |
52 Week Range | 0.4500 - 1.5800 |
Volume | |
Avg. Volume | 45,586 |
Market Cap | 14.093M |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.6220 |
Earnings Date | Mar 08, 2023 - Mar 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.50 |
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors w